IQVIA Holdings Inc (IQV)
Receivables turnover
Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue (ttm) | US$ in thousands | 14,308,000 | 14,246,000 | 14,145,000 | 14,033,000 | 14,004,000 | 13,925,000 | 13,769,000 | 13,666,000 | 13,470,000 | 13,226,000 | 12,614,000 | 11,671,000 | 11,033,000 | 10,630,000 | 10,575,000 | 10,800,000 | 10,726,000 | 10,519,000 | 10,377,000 | 10,209,000 |
Receivables | US$ in thousands | 3,381,000 | 3,227,000 | 3,139,000 | 3,063,000 | 2,917,000 | 2,640,000 | 2,679,000 | 2,619,000 | 2,551,000 | 2,330,000 | 2,276,000 | 2,361,000 | 2,410,000 | 2,414,000 | 2,371,000 | 2,634,000 | 2,582,000 | 2,514,000 | 2,401,000 | 2,461,000 |
Receivables turnover | 4.23 | 4.41 | 4.51 | 4.58 | 4.80 | 5.27 | 5.14 | 5.22 | 5.28 | 5.68 | 5.54 | 4.94 | 4.58 | 4.40 | 4.46 | 4.10 | 4.15 | 4.18 | 4.32 | 4.15 |
December 31, 2023 calculation
Receivables turnover = Revenue (ttm) ÷ Receivables
= $14,308,000K ÷ $3,381,000K
= 4.23
The receivables turnover of IQVIA Holdings Inc has shown a declining trend over the past eight quarters, decreasing from 5.32 in Q3 2022 to 4.39 in Q4 2023. This indicates that the company is taking longer to collect payments from its customers. A lower receivables turnover ratio may suggest potential issues with the company's credit policies, collection efforts, or the quality of its accounts receivable. It is important for IQVIA to closely monitor and improve its accounts receivable management to ensure efficient cash flow and timely collections.
Peer comparison
Dec 31, 2023
Company name
Symbol
Receivables turnover
IQVIA Holdings Inc
IQV
4.23
Arrowhead Pharmaceuticals Inc
ARWR
—
Charles River Laboratories
CRL
5.25
Exelixis Inc
EXEL
7.71
Incyte Corporation
INCY
—
Medpace Holdings Inc
MEDP
6.37